Most Popular
1. It’s a New Macro, the Gold Market Knows It, But Dead Men Walking Do Not (yet)- Gary_Tanashian
2.Stock Market Presidential Election Cycle Seasonal Trend Analysis - Nadeem_Walayat
3. Bitcoin S&P Pattern - Nadeem_Walayat
4.Nvidia Blow Off Top - Flying High like the Phoenix too Close to the Sun - Nadeem_Walayat
4.U.S. financial market’s “Weimar phase” impact to your fiat and digital assets - Raymond_Matison
5. How to Profit from the Global Warming ClImate Change Mega Death Trend - Part1 - Nadeem_Walayat
7.Bitcoin Gravy Train Trend Forecast 2024 - - Nadeem_Walayat
8.The Bond Trade and Interest Rates - Nadeem_Walayat
9.It’s Easy to Scream Stocks Bubble! - Stephen_McBride
10.Fed’s Next Intertest Rate Move might not align with popular consensus - Richard_Mills
Last 7 days
US Housing Market Analysis - Immigration Drives House Prices Higher - 30th Sep 24
Stock Market October Correction - 30th Sep 24
The Folly of Tariffs and Trade Wars - 30th Sep 24
Gold: 5 principles to help you stay ahead of price turns - 30th Sep 24
The Everything Rally will Spark multi year Bull Market - 30th Sep 24
US FIXED MORTGAGES LIMITING SUPPLY - 23rd Sep 24
US Housing Market Free Equity - 23rd Sep 24
US Rate Cut FOMO In Stock Market Correction Window - 22nd Sep 24
US State Demographics - 22nd Sep 24
Gold and Silver Shine as the Fed Cuts Rates: What’s Next? - 22nd Sep 24
Stock Market Sentiment Speaks:Nothing Can Topple This Market - 22nd Sep 24
US Population Growth Rate - 17th Sep 24
Are Stocks Overheating? - 17th Sep 24
Sentiment Speaks: Silver Is At A Major Turning Point - 17th Sep 24
If The Stock Market Turn Quickly, How Bad Can Things Get? - 17th Sep 24
IMMIGRATION DRIVES HOUSE PRICES HIGHER - 12th Sep 24
Global Debt Bubble - 12th Sep 24
Gold’s Outlook CPI Data - 12th Sep 24
RECESSION When Yield Curve Uninverts - 8th Sep 24
Sentiment Speaks: Silver Is Set Up To Shine - 8th Sep 24
Precious Metals Shine in August: Gold and Silver Surge Ahead - 8th Sep 24
Gold’s Demand Comeback - 8th Sep 24
Gold’s Quick Reversal and Copper’s Major Indications - 8th Sep 24
GLOBAL WARMING Housing Market Consequences Right Now - 6th Sep 24
Crude Oil’s Sign for Gold Investors - 6th Sep 24
Stocks Face Uncertainty Following Sell-Off- 6th Sep 24
GOLD WILL CONTINUE TO OUTPERFORM MINING SHARES - 6th Sep 24
AI Stocks Portfolio and Bitcoin September 2024 - 3rd Sep 24
2024 = 1984 - AI Equals Loss of Agency - 30th Aug 24
UBI - Universal Billionaire Income - 30th Aug 24
US COUNTING DOWN TO CRISIS, CATASTROPHE AND COLLAPSE - 30th Aug 24
GBP/USD Uptrend: What’s Next for the Pair? - 30th Aug 24
The Post-2020 History of the 10-2 US Treasury Yield Curve - 30th Aug 24
Stocks Likely to Extend Consolidation: Topping Pattern Forming? - 30th Aug 24
Why Stock-Market Success Is Usually Only Temporary - 30th Aug 24
The Consequences of AI - 24th Aug 24
Can Greedy Politicians Really Stop Price Inflation With a "Price Gouging" Ban? - 24th Aug 24
Why Alien Intelligence Cannot Predict the Future - 23rd Aug 24
Stock Market Surefire Way to Go Broke - 23rd Aug 24
RIP Google Search - 23rd Aug 24
What happened to the Fed’s Gold? - 23rd Aug 24
US Dollar Reserves Have Dropped By 14 Percent Since 2002 - 23rd Aug 24
Will Electric Vehicles Be the Killer App for Silver? - 23rd Aug 24
EUR/USD Update: Strong Uptrend and Key Levels to Watch - 23rd Aug 24
Gold Mid-Tier Mining Stocks Fundamentals - 23rd Aug 24
My GCSE Exam Results Day Shock! 2024 - 23rd Aug 24

Market Oracle FREE Newsletter

Category: BioTech

The analysis published under this category are as follows.

Companies

Tuesday, February 01, 2022

Unloved Biotech Stocks Sector / Companies / BioTech

By: Nadeem_Walayat

And the same it true for the unloved Biotech sector, where here's a taste of what to expect when I take a detail look at the biotech stocks. It's definitely going to take something special to buck the sector downtrend!

Read full article... Read full article...

 


Companies

Friday, November 05, 2021

Breakthrough Tech Could Give Billions Access To Healthcare / Companies / BioTech

By: Submissions

There’s a massive announcement set to take place later this year, and it could change the $12 trillion healthcare industry forever.

Over the last 2 years, we’ve seen a huge transformation as businesses across nearly every industry have gone digital.

And with the health crisis sweeping the globe last year, the healthcare sector was no different.

Read full article... Read full article...

 


Companies

Wednesday, November 03, 2021

The No.1 Biotech Stock Of 2021? / Companies / BioTech

By: Submissions

It’s an industry that will never retire or ever go obsolete.
It’s a revolutionary virtual marketplace, and it’s one of the fastest-growing markets on the planet.

The world has gone full-on mobile, and nothing is nothing anymore without an app.

The global mobile app sector generated over $365 billion in revenue in 2018 …

In just a year-and-a-half, it will exceed $935 billion in revenue via paid downloads and in-app advertising.

But more importantly, investing in early-stage app development can be one of the quickest ways to make 10X…20X...50X...and even 100X returns on your investment.

Read full article... Read full article...

 


Companies

Tuesday, October 19, 2021

The Most Exciting Medical Breakthrough Of The Decade? / Companies / BioTech

By: OilPrice_Com

According to Google’s Health boss David Feinberg... over one billion people a day search Google for health concerns.
 
But, what if, instead... they could "consult" a phone app with the power of hundreds of doctors?
 
That's exactly what will be available weeks from now when Treatment.com’s (CSE: TRUE; OTC: TREIF) and their big tech platform for healthcare, deliver the breakthrough  AI app Cara launches.
 
After five years in beta, we think that they are about to disrupt the $11.8 trillion healthcare industry.
Read full article... Read full article...

 


Companies

Monday, October 18, 2021

A.I. Breakthrough Could Disrupt the $11 Trillion Medical Sector / Companies / BioTech

By: OilPrice_Com

A massive disruption now appears imminent in one of the world’s largest – and most important – industries.

In much the same way that Amazon disrupted the retail business – and how PayPal disrupted the payments industry – one under-the-radar health technology company now seeks to transform the $11.85 trillion global health industry.
 
By moving healthcare away from brick and mortar, traditional medicine into an AI-driven tool that offers unprecedented speed, efficiency, and accuracy...

Read full article... Read full article...

 


Companies

Monday, October 04, 2021

Chasing Value with Five More Biotech Stocks for the Long-run / Companies / BioTech

By: Nadeem_Walayat

Five more biotech stocks to add to the strategy of invest and forget for a potential X10 return. a reminder of why I am engaging in this binge on biotech stocks after having been focused on AI stocks for the past 5 years.

1. Biotech stocks are an unloved stocks sector whilst tech stocks over valued, even the ultra safe stocks such as the Top 10, so I am reluctant to add at current valuations hence why I hit the SELL button for the first time in many years and reduced my exposure to AI stocks by about 40%.

2. That biotech is a derivative of AI, we'll most sectors will soon become a derivative of AI because it is the PRIMARY tech megatrend of our age that will continue to broaden its reach to encompass all sectors of the economy.

Read full article... Read full article...

 


Companies

Sunday, October 03, 2021

Aptorum Group - APM - High RIsk Biotech Stocks Buy, Sell, Hold Investing Analysis for the Long-run / Companies / BioTech

By: Nadeem_Walayat

Five more biotech stocks to add to the strategy of invest and forget for a potential X10 return. a reminder of why I am engaging in this binge on biotech stocks after having been focused on AI stocks for the past 5 years.

1. Biotech stocks are an unloved stocks sector whilst tech stocks over valued, even the ultra safe stocks such as the Top 10, so I am reluctant to add at current valuations hence why I hit the SELL button for the first time in many years and reduced my exposure to AI stocks by about 40%.

2. That biotech is a derivative of AI, we'll most sectors will soon become a derivative of AI because it is the PRIMARY tech megatrend of our age that will continue to broaden its reach to encompass all sectors of the economy.

3. That one of my former biotech 12xers got taken over (GW Pharma) that flooded my account with cash early May and so that focused my attention on repopulating my portfolio with 10 more biotech stocks where I expect at least 3 to 10x, with most of the rest expected to survive to varying extent. Though this is the stock market and so there are never any guarantees especially where such smallish cap stocks are concerned.

Read full article... Read full article...

 


Companies

Thursday, September 30, 2021

BioDelivery Sciences International - BDSI - High RIsk Biotech Stocks Buy, Sell, Hold Investing Analysis for the Long-run / Companies / BioTech

By: Nadeem_Walayat

Five more biotech stocks to add to the strategy of invest and forget for a potential X10 return. a reminder of why I am engaging in this binge on biotech stocks after having been focused on AI stocks for the past 5 years.

1. Biotech stocks are an unloved stocks sector whilst tech stocks over valued, even the ultra safe stocks such as the Top 10, so I am reluctant to add at current valuations hence why I hit the SELL button for the first time in many years and reduced my exposure to AI stocks by about 40%.

2. That biotech is a derivative of AI, we'll most sectors will soon become a derivative of AI because it is the PRIMARY tech megatrend of our age that will continue to broaden its reach to encompass all sectors of the economy.

3. That one of my former biotech 12xers got taken over (GW Pharma) that flooded my account with cash early May and so that focused my attention on repopulating my portfolio with 10 more biotech stocks where I expect at least 3 to 10x, with most of the rest expected to survive to varying extent. Though this is the stock market and so there are never any guarantees especially where such smallish cap stocks are concerned.

Read full article... Read full article...

 


Companies

Wednesday, September 29, 2021

Takeda - TAK - High RIsk Biotech Stocks Buy, Sell, Hold Investing Analysis for the Long-run / Companies / BioTech

By: Nadeem_Walayat

Five more biotech stocks to add to the strategy of invest and forget for a potential X10 return. a reminder of why I am engaging in this binge on biotech stocks after having been focused on AI stocks for the past 5 years.

1. Biotech stocks are an unloved stocks sector whilst tech stocks over valued, even the ultra safe stocks such as the Top 10, so I am reluctant to add at current valuations hence why I hit the SELL button for the first time in many years and reduced my exposure to AI stocks by about 40%.

2. That biotech is a derivative of AI, we'll most sectors will soon become a derivative of AI because it is the PRIMARY tech megatrend of our age that will continue to broaden its reach to encompass all sectors of the economy.

3. That one of my former biotech 12xers got taken over (GW Pharma) that flooded my account with cash early May and so that focused my attention on repopulating my portfolio with 10 more biotech stocks where I expect at least 3 to 10x, with most of the rest expected to survive to varying extent. Though this is the stock market and so there are never any guarantees especially where such smallish cap stocks are concerned.

Read full article... Read full article...

 


Companies

Tuesday, September 28, 2021

Cara Therapeutics - CARA - High RIsk Biotech Stocks Buy, Sell, Hold Investing Analysis for the Long-run / Companies / BioTech

By: Nadeem_Walayat

Five more biotech stocks to add to the strategy of invest and forget for a potential X10 return. a reminder of why I am engaging in this binge on biotech stocks after having been focused on AI stocks for the past 5 years.

1. Biotech stocks are an unloved stocks sector whilst tech stocks over valued, even the ultra safe stocks such as the Top 10, so I am reluctant to add at current valuations hence why I hit the SELL button for the first time in many years and reduced my exposure to AI stocks by about 40%.

2. That biotech is a derivative of AI, we'll most sectors will soon become a derivative of AI because it is the PRIMARY tech megatrend of our age that will continue to broaden its reach to encompass all sectors of the economy.

3. That one of my former biotech 12xers got taken over (GW Pharma) that flooded my account with cash early May and so that focused my attention on repopulating my portfolio with 10 more biotech stocks where I expect at least 3 to 10x, with most of the rest expected to survive to varying extent. Though this is the stock market and so there are never any guarantees especially where such smallish cap stocks are concerned.

Read full article... Read full article...

 


Companies

Monday, September 27, 2021

Blueprint Medicines - BPMC - High RIsk Biotech Stocks Buy, Sell, Hold Investing Analysis for the Long-run / Companies / BioTech

By: Nadeem_Walayat

Five more biotech stocks to add to the strategy of invest and forget for a potential X10 return. a reminder of why I am engaging in this binge on biotech stocks after having been focused on AI stocks for the past 5 years.

1. Biotech stocks are an unloved stocks sector whilst tech stocks over valued, even the ultra safe stocks such as the Top 10, so I am reluctant to add at current valuations hence why I hit the SELL button for the first time in many years and reduced my exposure to AI stocks by about 40%.

2. That biotech is a derivative of AI, we'll most sectors will soon become a derivative of AI because it is the PRIMARY tech megatrend of our age that will continue to broaden its reach to encompass all sectors of the economy.

3. That one of my former biotech 12xers got taken over (GW Pharma) that flooded my account with cash early May and so that focused my attention on repopulating my portfolio with 10 more biotech stocks where I expect at least 3 to 10x, with most of the rest expected to survive to varying extent. Though this is the stock market and so there are never any guarantees especially where such smallish cap stocks are concerned.

Read full article... Read full article...

 


Companies

Tuesday, July 27, 2021

Chasing Value in Unloved by Markets Small Cap Biotech Stocks for the Long-run / Companies / BioTech

By: Nadeem_Walayat

Five more biotech stocks to add to the strategy of invest and forget for a potential X10 return. a reminder of why I am engaging in this binge on biotech stocks after having been focused on AI stocks for the past 5 years.

1. Biotech stocks are an unloved stocks sector whilst tech stocks over valued, even the ultra safe stocks such as the Top 10, so I am reluctant to add at current valuations hence why I hit the SELL button for the first time in many years and reduced my exposure to AI stocks by about 40%.

2. That biotech is a derivative of AI, we'll most sectors will soon become a derivative of AI because it is the PRIMARY tech megatrend of our age that will continue to broaden its reach to encompass all sectors of the economy.

Read full article... Read full article...

 


Companies

Sunday, July 04, 2021

Atea Pharmaceuticals - AVIR - X10 Stock for Max Risk / Companies / BioTech

By: Nadeem_Walayat

Life Sciences Biotech Smaller Cap High Risk Stocks Investing Binge

Why has my focus shifted to biotech stocks and not more tech stocks?

Firstly, I have been investing in biotech stocks for DECADES, it's just that since 2015 my focus shifted to the emerging AI mega-trend to make sure I was invested to capitalise on a trend that was clear to me would span DECADES, at the time I thought I was probably getting in late on the AI Mega-trend but clearly that is always the case! WE ALWAYS THINK we're late to the party but this trend is going to run right into the end of the 2030's

This also explains why I hold the likes of GSK and JNJ amongst a string of smaller cap biotech stocks many of which have been disappearing from my portfolio over the years usually due to being taken over as it looks likely to be the case for GW Pharma later this year. So I need to replenish this once much loved and now neglected stock sector with a string of new smaller cap high risk stocks for the next 5 to 10 years.

Read full article... Read full article...

 


Companies

Saturday, July 03, 2021

Neurocrine Biosciences - NBIX - Low Risk Biotech X10 Stock / Companies / BioTech

By: Nadeem_Walayat

Life Sciences Biotech Smaller Cap High Risk Stocks Investing Binge

Why has my focus shifted to biotech stocks and not more tech stocks?

Firstly, I have been investing in biotech stocks for DECADES, it's just that since 2015 my focus shifted to the emerging AI mega-trend to make sure I was invested to capitalise on a trend that was clear to me would span DECADES, at the time I thought I was probably getting in late on the AI Mega-trend but clearly that is always the case! WE ALWAYS THINK we're late to the party but this trend is going to run right into the end of the 2030's

This also explains why I hold the likes of GSK and JNJ amongst a string of smaller cap biotech stocks many of which have been disappearing from my portfolio over the years usually due to being taken over as it looks likely to be the case for GW Pharma later this year. So I need to replenish this once much loved and now neglected stock sector with a string of new smaller cap high risk stocks for the next 5 to 10 years.

Secondly, our beloved AI stocks have been BID UP to high valuations, yes including Google, so they are not CHEAP, even after a 10% to 15% correction i.e. the likes of Microsoft and Amazon are discounting a lot of future earnings growth! Of course that does not necessarily mean that they are about to fall to what I would consider to be fair value let lone cheap levels as they did during March 2020 because at the end of the day they are GOOD stocks so usually command a healthy premium to invest in.

Read full article... Read full article...

 


Companies

Friday, July 02, 2021

CRISPR - CRSP - GENE EDITING Stock Analysis - Risk Level 9 / Companies / BioTech

By: Nadeem_Walayat

Life Sciences Biotech Smaller Cap High Risk Stocks Investing Binge

Why has my focus shifted to biotech stocks and not more tech stocks?

Firstly, I have been investing in biotech stocks for DECADES, it's just that since 2015 my focus shifted to the emerging AI mega-trend to make sure I was invested to capitalise on a trend that was clear to me would span DECADES, at the time I thought I was probably getting in late on the AI Mega-trend but clearly that is always the case! WE ALWAYS THINK we're late to the party but this trend is going to run right into the end of the 2030's

This also explains why I hold the likes of GSK and JNJ amongst a string of smaller cap biotech stocks many of which have been disappearing from my portfolio over the years usually due to being taken over as it looks likely to be the case for GW Pharma later this year. So I need to replenish this once much loved and now neglected stock sector with a string of new smaller cap high risk stocks for the next 5 to 10 years.

Read full article... Read full article...

 


Companies

Thursday, July 01, 2021

ABBVIE - ABBV 116 - Cheap Low Risk Pharma Stock Investing - Risk 1 / Companies / BioTech

By: Nadeem_Walayat

Life Sciences Biotech Smaller Cap High Risk Stocks Investing Binge

Why has my focus shifted to biotech stocks and not more tech stocks?

Firstly, I have been investing in biotech stocks for DECADES, it's just that since 2015 my focus shifted to the emerging AI mega-trend to make sure I was invested to capitalise on a trend that was clear to me would span DECADES, at the time I thought I was probably getting in late on the AI Mega-trend but clearly that is always the case! WE ALWAYS THINK we're late to the party but this trend is going to run right into the end of the 2030's

This also explains why I hold the likes of GSK and JNJ amongst a string of smaller cap biotech stocks many of which have been disappearing from my portfolio over the years usually due to being taken over as it looks likely to be the case for GW Pharma later this year. So I need to replenish this once much loved and now neglected stock sector with a string of new smaller cap high risk stocks for the next 5 to 10 years.

Secondly, our beloved AI stocks have been BID UP to high valuations, yes including Google, so they are not CHEAP, even after a 10% to 15% correction i.e. the likes of Microsoft and Amazon are discounting a lot of future earnings growth! Of course that does not necessarily mean that they are about to fall to what I would consider to be fair value let lone cheap levels as they did during March 2020 because at the end of the day they are GOOD stocks so usually command a healthy premium to invest in.

Read full article... Read full article...

 


Companies

Thursday, June 24, 2021

Life Sciences Biotech Smaller Cap High Risk Stocks Investing Binge / Companies / BioTech

By: Nadeem_Walayat

Why has my focus shifted to biotech stocks and not more tech stocks?

Firstly, I have been investing in biotech stocks for DECADES, it's just that since 2015 my focus shifted to the emerging AI mega-trend to make sure I was invested to capitalise on a trend that was clear to me would span DECADES, at the time I thought I was probably getting in late on the AI Mega-trend but clearly that is always the case! WE ALWAYS THINK we're late to the party but this trend is going to run right into the end of the 2030's

Read full article... Read full article...

 


Companies

Friday, June 11, 2021

Big Pharma Is Back! Biotech Skyrockets On Biogen’s New Alzheimer Drug Approval / Companies / BioTech

By: Chris_Vermeulen

The FDA issued an accelerated approval status for Biogen’s new Alzheimer drug with specific requirements related to consumer use and results.  In these cases, the FDA is allowing Biogen to move into a more open consumer trial where the results and side-effects of this new drug will be identified fairly quickly.

This new drug targets the plague in the heart and brain that is associated with Alzheimer’s.  Over five million Americans live with some form of Alzheimer’s currently.  The Alzheimers Association continues to provide detailed statistics related to how this disease relates to various segments of American society.  You can read more about how big this announcement is in terms of how Alzheimer’s affects Americans in this 2019 Alzheimer’s Disease Facts And Figures report.

This news of a new Biogen Alzheimer’s drug has sent XBI skyrocketing – yet the news may not be enough to continue to trend across an entire market sector.  The one thing that I would like to point out is that news of a single drug that has entered early-stage accelerated approval by the FDA does not make a new trend – it makes a news blip.

Read full article... Read full article...

 


Companies

Friday, May 21, 2021

3 World-Shaking Trends Investors Need To Watch This Year / Companies / BioTech

By: FinancialMorningPost

...

 


Companies

Thursday, May 20, 2021

Is This The Most Exciting Healthcare Development Of The Year? / Companies / BioTech

By: FinancialMorningPost

...

 


Page << | 1 | 2 | 3 | 4 | >>